Apixaban used for the management of heparin‐induced thrombocytopenia in a 72‐year‐old woman with lung cancer. Issue 12 (29th October 2015)

• Record Type: Journal Article
• Authors: Larsen, Pia Bükmann; Jørgensen, Maja; Friis‐Hansen, Lennart; Ingeberg, Steen
• Is Part Of: Clinical case reports. Volume 3:Issue 12(2015:Dec.)
• Page Start: 987
• Page End: 989
• Publication Date: 2015-10-29
• Subjects: Apixaban -- cancer -- dalteparin -- heparin‐induced thrombocytopenia; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.411
• Languages: English
• ISSNs: 2050-0904

Abstract

Key Clinical Message: Heparin‐induced thrombocytopenia (HIT) is a serious adverse reaction to heparin treatment with a high risk of thrombosis. Heparin must be discontinued immediately and replaced with alternative anticoagulants that do not interact with HIT antibodies. In this case, a lung cancer patient, diagnosed with HIT was successfully treated with apixaban. Abstract : Heparin‐induced thrombocytopenia (HIT) is a serious adverse reaction to heparin treatment with a high risk of thrombosis. Heparin must be discontinued immediately and replaced with alternative anticoagulants that do not interact with HIT antibodies. In this case, a lung cancer patient, diagnosed with HIT was successfully treated with apixaban.